Merck -- 5.8/10 -- $120.87

WATCHLIST
NYSE: MRK  |  Global pharma leader anchored by Keytruda (~49% of revenue, $31.7B), vaccines (Gardasil, Capvaxive), and animal health. Near 52-week highs at $121, up 65% from $73 lows. Trailing P/E 16.6x on $64.5B revenue. Dividend yield 2.81%. Keytruda LOE in 2028-2029 is the largest single-product patent cliff in pharma history. Winrevair ($1.4B Year 1) and pipeline (~80 Phase III trials) are bright spots, but concentration risk is worsening -- not improving -- as Gardasil collapsed -39% YoY on China implosion. 2026 guidance is cautious: +1-3% revenue growth, flat adjusted EPS. Next earnings late April 2026.
FY2025 Revenue
$64.5B
+1.9% YoY | Keytruda +7.5% | Gardasil -39%
FY2025 Free Cash Flow
$12.4B
-32% YoY | 4.1% FCF yield on $299B mkt cap
Trailing P/E
16.6x
EPS (TTM) $7.28 | Div yield 2.81%
Composite Score
5.8 / 10
WATCHLIST - Keytruda cliff overhang
Quality gate results
Oligopoly / Dominant Position
PASS
Keytruda is the dominant PD-1 checkpoint inhibitor globally with ~$31.6B in 2025 revenue, roughly 2.5-3x the nearest competitor (Opdivo ~$9-10B, BMS). The PD-1/PD-L1 market is effectively a duopoly at the top. However, this dominance is time-limited: IV patent expiry Dec 2028, with IRA negotiated pricing effective 2029. Subcutaneous Keytruda (QLEX) is an LOE mitigation strategy, not a moat extension.
Positive and Growing FCF
PASS (declining)
FCF was $12.4B in FY2025, positive and substantial, but declined -32% from $18.1B in FY2024. The decline reflects lower Gardasil cash contribution and increased investment in pipeline and manufacturing. FCF yield of ~4.1% on the current market cap is reasonable. The direction of FCF is the concern -- declining, not growing.
Management 3+ Year Track Record
PASS
CEO Rob Davis (since 2021, prior CFO) leads a stable team with CFO Caroline Litchfield and R&D President Dean Li. Promise tracking shows strong execution: revenue and EPS guidance met in 2024 and 2025, Winrevair launch exceeded expectations, subcutaneous Keytruda approved on schedule. Key miss: withdrew $11B Gardasil target as China collapsed. Overall credible and consistent.

Gate result: Two of three gates are clean passes; FCF passes on absolute level but the declining trajectory is a yellow flag. Keytruda dominance is genuine but time-limited (LOE 2028-2029). Management has earned credibility through consistent execution and honest communication when things went wrong (Gardasil China withdrawal). The gates do not disqualify Merck, but the declining FCF and time-limited oligopoly warrant caution.

Score breakdown
6
/ 10
Financial Trends Weight: 25%
Revenue grew +1.9% YoY to $64.5B in FY2025 -- low-single-digit growth masking a bifurcated story. Keytruda grew +7.5% to $31.7B but is decelerating (from +18% in 2024). Gardasil collapsed -39% to $5.2B on a China implosion (-71.5%). Winrevair launched exceptionally ($1.4B Year 1, +244%). Non-GAAP EPS grew +17.4% to $8.98 on operating leverage. Gross margin expanded to 81.5%. FCF declined -32% to $12.4B. 2026 guided at +1-3% revenue, flat adjusted EPS. Concentration is worsening: Keytruda is now 49% of revenue, up from 30% in 2020.
6
/ 10
Thematic Exposure Weight: 25%
Oncology (PD-1 dominance), vaccines, and cardiovascular (Winrevair in PAH) are strong secular themes. Keytruda has ~2.5-3x the revenue of nearest PD-1 competitor. Pipeline includes ~80 Phase III trials across oncology, immunology, cardiovascular, and infectious disease. However, theme quality is undermined by time-limited exclusivity -- the Keytruda franchise faces the largest LOE in pharma history. Gardasil China headwinds further dampen the vaccine theme. Winrevair and pipeline optionality are genuine but unproven at the scale needed.
7
/ 10
Management Quality Weight: 20%
CEO Rob Davis and team have delivered consistent execution: FY2024 and FY2025 revenue and EPS guidance met, Winrevair launch exceeded expectations, subcutaneous Keytruda approved on schedule. Key miss was withdrawing the $11B Gardasil target when China collapsed -- but the withdrawal itself was honest and timely. Davis frames the Keytruda cliff as a hill, citing $70B+ non-risk-adjusted pipeline opportunity. Conservative guidance-setting with consistent delivery. Stable leadership team since 2021. Pipeline strategy (Sidera, Verona acquisitions) shows proactive diversification.
4
/ 10
Investor Sentiment Weight: 15%
Stock rallied ~65% from $73 lows to $121, now within 3% of 52-week highs. The narrative has flipped from Keytruda cliff panic to consensus comfort. 18 Buy / 11 Hold / 0 Sell with avg PT of ~$128-131 (only 6-9% upside). No bears remain. The contrarian opportunity at $73 has been fully harvested. Institutional ownership ~76%, heavily passive. Crowded positioning with limited margin of safety at current levels.
5
/ 10
Concerns, Catalysts & Risks Weight: 15%
Deeply bifurcated risk/reward. Near-term execution is solid, but Keytruda LOE (Dec 2028 IV patent, IRA pricing 2029) is the defining overhang -- $32-35B peak revenue at risk. Gardasil China has no visible trough. 2026 guidance implies a heavy investment year with flat returns. Catalysts: Winrevair label expansion, subcu Keytruda adoption, pipeline readouts (islatravir, MK3000, MK1406). Risks: concentration worsening, FCF declining, valuation not cheap on guided EPS. BMY trades at 9.5x as a comp for where MRK could compress post-LOE.
Dimension Score Weight Weighted
Financial Trends 6 25% 1.50
Thematic Exposure 6 25% 1.50
Management Quality 7 20% 1.40
Investor Sentiment 4 15% 0.60
Concerns, Catalysts & Risks 5 15% 0.75
Composite 100% 5.8
Company overview

Merck is a global pharmaceutical leader with $64.5B in FY2025 revenue, anchored by Keytruda -- the dominant PD-1 checkpoint inhibitor with $31.7B in sales (~49% of total revenue). The company operates across oncology, vaccines (Gardasil, Capvaxive), cardiovascular (Winrevair), and animal health (~10% of revenue). Calendar fiscal year, headquartered in Rahway, New Jersey.

The investment case is defined by a single question: can Merck replace $30B+ of Keytruda revenue before the patent cliff hits? Keytruda IV exclusivity expires Dec 2028, with IRA negotiated pricing effective 2029. Management claims $70B+ of non-risk-adjusted commercial opportunity by mid-2030s and frames the cliff as more of a hill. The pipeline is the broadest in company history (~80 Phase III trials), and recent launches are performing: Winrevair reached $1.4B in its first full year (+244%), Capvaxive launched to $759M, and subcutaneous Keytruda (QLEX) was approved on schedule.

The challenge is that concentration is getting worse, not better. Keytruda was 30% of revenue in 2020 and is now 49%. Gardasil collapsed -39% in FY2025 on a China implosion (-71.5%), and Lagevrio is fading. Non-Keytruda revenue actually declined from 2023 to 2025 despite new launches, because legacy headwinds exceeded new product tailwinds. Total revenue growth decelerated to +1.9%, FCF declined -32%, and 2026 guidance implies another heavy investment year with flat adjusted returns. The stock has rallied 65% from its lows and trades near 52-week highs with a crowded consensus (18 Buy / 11 Hold / 0 Sell).

Price $120.87 FY2025 Revenue $64.5B (+1.9% YoY)
Market Cap $298.8B FY2025 Non-GAAP Gross Margin 81.5% (up from 74.3% in 2020)
Trailing P/E 16.6x Non-GAAP EPS (FY25) $8.98 (+17.4% YoY)
52-Week Range $73.31 - $125.14 FCF (FY2025) $12.4B (-32% YoY)
Dividend Yield 2.81% Keytruda (FY2025) $31.7B (+7.5% YoY, 49% of rev)
50-Day / 200-Day Avg $117 / $96 Next Earnings Late April 2026
Summary thesis

MRK receives a composite score of 5.8/10, reflecting credible management execution (7) and decent financials (6) and thematic positioning (6), offset by crowded sentiment (4) after a 65% rally and elevated risk (5) from the approaching Keytruda cliff. The score sits at the borderline between HOLD and AVOID.

Bull case (~$145-160, +20-32%): Keytruda decelerates gracefully while subcutaneous Keytruda gains traction post-J-code (April 2026). Winrevair exceeds $2.5B in 2026 with label expansion into additional PH subtypes. Gardasil China stabilizes. Pipeline catalysts de-risk the $70B opportunity claim (islatravir, MK1406, ADCs). Multiple re-rates to 20-22x on visibility of post-LOE growth. Dividend provides downside cushion.

Base case (~$115-135, -5% to +12%): FY2026 delivers guided +1-3% revenue growth. Keytruda grows mid-single digits. Gardasil remains depressed. Winrevair hits $2B+. Adjusted EPS roughly flat at ~$8.65-8.80. Stock trades sideways as the market waits for proof that the pipeline can offset the cliff. 16-17x P/E sustained by dividend and near-term earnings stability.

Bear case (~$80-95, -20-35%): Keytruda growth stalls below +5%. Gardasil China deteriorates further with no trough. Pipeline setbacks (Phase III failures in key programs) undermine the $70B narrative. FCF continues declining. The market begins pricing MRK like BMY (9.5x) as the LOE approaches. Multiple compresses to 12-14x guided EPS.

Bottom line: Merck is a well-managed pharma company executing competently against the largest single-product patent cliff in history. The pipeline is deep and management is credible, but the concentration problem is worsening, the Gardasil franchise is in freefall, and the stock has already priced in the easy part of the recovery. At $121, with 0 Sell ratings and only 6-9% upside to consensus PT, the margin of safety is thin. WATCHLIST, with upgrade triggers: (1) Gardasil China stabilization providing visibility to a trough, (2) pipeline catalysts (MK1406 Phase III, ADC readouts) de-risking the post-LOE narrative, (3) stock pullback to $95-100 range (12-13x TTM) offering better entry. Any two of three would warrant a constructive view.

What to watch

Key catalysts and monitoring points:

For the full analysis, see the Financials, Thematics, Management, and Sentiment pages.

Data sourced from Daloopa (company_id: 484) and MRK earnings transcripts (Q3 2024 through Q4 2025).